FDA Enforcement Priorities: Eye Products, Dual Drug/Cosmetic Firms
This article was originally published in The Rose Sheet
Executive Summary
When FDA inspects a facility producing both drugs and cosmetics, the manufacturer should be using one standard and that’s the drug standard, says Karyn Campbell, director of the investigations branch at FDA’s Philadelphia District Office.
You may also be interested in...
FDA Warns Foreign Personal-Care Firms For Monograph, GMP Violations
An August letter to Jabones Pardo is the latest in a string of FDA warnings to international firms that market personal-care products for acne treatment, pain relief and other indications in violation of U.S. drug regulations. Warnings to OTC product firms outside the U.S. over the past two years reflect the higher priority FDA has assigned to inspecting international firms.
Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012
“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.
FDA Flags Chinese Personal-Care Firm For Drug GMP Failings
The agency will pursue cosmetics and personal-care product companies as pharmaceutical manufacturers if their product labeling strays into drug territory. FDA’s warning letter to Shanghai Huhui Daily Use Chemical Products says its skin protectant cream does not comply with the OTC monograph.